| abstract |
The disclosure relates to (i) a MET inhibitor that is INC280 or a pharmaceutically acceptable salt or hydrate thereof, and (ii) a monoclonal antibody such as cetuximab or panitumumab, which are jointly active in the treatment of proliferative diseases Relates to pharmaceutical products comprising a combination of EGFR inhibitors, corresponding pharmaceutical formulations, uses, methods, processes, commercial packages and related embodiments. |